Abstract
Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan.
Publication types
-
Clinical Trial
-
Comparative Study
-
Letter
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Anti-Arrhythmia Agents / adverse effects
-
Anti-Arrhythmia Agents / therapeutic use*
-
Captopril / adverse effects
-
Captopril / therapeutic use*
-
Cardiotonic Agents / adverse effects
-
Cardiotonic Agents / therapeutic use*
-
Death, Sudden, Cardiac / epidemiology
-
Death, Sudden, Cardiac / prevention & control
-
Electrocardiography / drug effects*
-
Heart Failure / drug therapy*
-
Heart Failure / mortality
-
Humans
-
Long QT Syndrome / drug therapy*
-
Long QT Syndrome / mortality
-
Losartan / adverse effects
-
Losartan / therapeutic use*
-
Survival Rate
-
Treatment Outcome
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Anti-Arrhythmia Agents
-
Cardiotonic Agents
-
Captopril
-
Losartan